MAS1L and metabolic dysfunction-associated steatohepatitis: In our cohort of patients with grade II–III obesity undergoing evaluation for bariatric surgery, MASLD prevalence was higher (85.8%), with lower MASL prevalence (36.9%) and higher prevalence of MASH (48.9%) and fibrosis (26%).